Martina Rojnic-Kuzman, Croatia
Zagreb School of Medicine and ZagUniversity Hospital Centre Department of PsychiatryPresenter of 3 Presentations
Board Meeting
- Julian Beezhold, United Kingdom
- Geert Dom, Belgium
- Peter Falkai, Germany
- Andrea Fiorillo, Italy
- Silvana Galderisi, Italy
- Philip A. Gorwood, France
- Cecile Hanon, France
- Hilkka M. Kärkkäinen, Finland
- Tamas Kurimay, Hungary
- Miia Männikkö, Finland
- Diego Palao Vidal, Spain
- Mariana Pinto da Costa, United Kingdom
- Andrea Raballo, Italy
- Martina Rojnic-Kuzman, Croatia
- Meryam Schouler-Ocak, Germany
- Agata Szulc, Poland
- Danuta Wasserman, Sweden
- Michael E. Wise, United Kingdom
- Simavi Vahip, Turkey
- Julian Beezhold, United Kingdom
- Geert Dom, Belgium
- Peter Falkai, Germany
- Andrea Fiorillo, Italy
- Silvana Galderisi, Italy
- Philip A. Gorwood, France
- Cecile Hanon, France
- Hilkka M. Kärkkäinen, Finland
- Tamas Kurimay, Hungary
- Miia Männikkö, Finland
- Diego Palao Vidal, Spain
- Mariana Pinto da Costa, United Kingdom
- Andrea Raballo, Italy
- Martina Rojnic-Kuzman, Croatia
- Meryam Schouler-Ocak, Germany
- Agata Szulc, Poland
- Danuta Wasserman, Sweden
- Michael E. Wise, United Kingdom
- Simavi Vahip, Turkey
Opening address
Can Psychosocial Treatment Reduce Antipsychotic-Induced Metabolic Disturbances in Patients with First Episode Psychosis? - S152
Abstract
Abstract Body
Weight gain and metabolic abnormalities associated with antipsychotic medication are major challenges in the treatment of patients with first episode psychosis. Unfortunately, current strategies for preventing or reducing these side effects are not successful. This study aims to analyse the effects of a multimodal treatment program for first episode psychosis on metabolic changes during the first 18th months of treatment. 71 patients who were treated at the Zagreb University Hospital Centre for first acute psychotic episode from 2016 until 2018, were included in the study. After 3-4-week long hospital treatment, patients attended either the day hospital program or treatment as usual (TAU) consisting of short outpatients visit once a month. We monitored baseline and final body weight, blood glucose, lipids and cholesterol as primary outcome measures and psychopathology and global level of functioning as secondary outcome measures. After the adjustment for age, gender and baseline measures, the type of treatment was not significantly associated with any of the primary outcome measures and both types of treatment were relatively ineffective in counteracting medication-induced metabolic abnormalities and weight gain. Patients' psychopathology measures significantly decreased, and their functional level significantly increased at month 18th compared to the baseline values in both groups. Thus, even though both treatment options reduced psychopathology and helped restoring the patients' level of functioning over the first 18 months of treatment, it is possible that over a longer period the negative effect of medication associated metabolic side effects may surpass the beneficial effect on the psychiatric disorder.